4.5 Article

The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study

Related references

Note: Only part of the references are listed.
Article Oncology

Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526)

Juanita Crook et al.

Summary: This is the first prospective multicenter trial reporting outcomes of salvage low-dose-rate prostate brachytherapy for local failure after external beam radiation therapy. The 5-year freedom from biochemical failure rate is 68%, comparable to other salvage modalities. Although further local failure is rare (5%), biochemical failure rate climbs to 46% by 10 years.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

Review Urology & Nephrology

A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)

Luca F. Valle et al.

Summary: In the management of locally recurrent prostate cancer after definitive radiotherapy, salvage treatment modalities show similar 5-yr recurrence-free survival rates compared to RP, but reirradiation may result in lower toxicity.

EUROPEAN UROLOGY (2021)

Article Oncology

Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response

Kyle Wang et al.

Summary: Multiple studies have shown that prostate SBRT therapy is well tolerated overall with mainly mild to moderate toxicities and very low incidence of severe toxicities. Side effects are influenced by both dosimetric and non-dosimetric factors. Further research is needed to explore tolerance doses in the future.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Article Oncology

The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers

Tadeusz Dyba et al.

Summary: This article presents the incidence and mortality estimates for 25 major cancers across 40 individual countries within European areas and the EU-27 for the year 2020. The most common cancers are breast, colorectal, lung, and prostate cancers, which account for half the overall cancer burden in Europe. The estimates provide a basis for setting priorities in cancer-control measures across Europe.

EUROPEAN JOURNAL OF CANCER (2021)

Review Oncology

Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus

Barbara A. Jereczek-Fossa et al.

Summary: This study investigated expert opinions on salvage SBRT for intraprostatic relapse after RT. Through three rounds of Delphi consensus, experts reached a certain level of consensus on selection criteria, diagnostic procedures, and therapeutic approaches.

CANCER TREATMENT REVIEWS (2021)

Article Oncology

Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT

Donald Fuller et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)

Review Oncology

A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer

Pieter J. L. De Visschere et al.

EUROPEAN UROLOGY ONCOLOGY (2019)

Article Urology & Nephrology

Salvage Cryotherapy for Radiation-Recurrent Prostate Cancer: Outcomes and Complications

David S. Finley et al.

Current Urology Reports (2011)

Article Medicine, General & Internal

Development and validation of a prognostic index for 4-year mortality in older adults

SJ Lee et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)